CMP INR: 1,098

Emami Ltd. Target Price INR: 1,210

Expected Return: 10%
EDELSTAR • FUNDAMENTAL RESEARCH Date: 18th June, 2018

Business Overview QUICK DATA

Emami is a leading FMCG player in India, operating in certain attractive
segments such as skin care and hair oil. The company is promoted by
Face Value (Rs.) 1.0
Kolkata‐based industrialists, Mr. R. S. Agarwal and Mr. R. S. Goenka. The
company has been operating in health, beauty and personal care Div. Yield (%) 0.6
products for the past 30+ years and has sustained a prominent position No of shares ('mn) 227
in therapeutic and Ayurvedic based products, ensuring strong entry 52-week High/Low (Rs.) 1365 /1001
barriers for competition. Over the years, Emami has innovated and built
NSE Symbol EMAMILTD
block‐buster brands such as Navratna, Boroplus, and Fair and
Handsome. With the acquisition of ‘Zandu’, another strong Ayurvedic BSE Code 531162
brand was added to the portfolio. Emami recently forayed into female Edel Code EMALTD
hygiene space by acquisition of SHE (no.4 player in the category with Market cap (Rs. bn) 250
1.1% market share). The company recently acquired Kesh King
(portfolio includes ayurvedic medicinal oil, aloe vera herbal shampoo
and conditioner and ayurvedic capsules) which is a leader in the SHAREHOLDING PATTERN (%)
ayurvedic hair and scalp care category.
Promoters 72.7

Key highlights MFs, FIs & Banks 5.5

 Emami’s product portfolio provides a play on Indian FMCG FIIs 13.1
spend by virtue of its strong presence in less penetrated and Others 8.7
high growth categories. More than 80% of Emami’s products
have Ayurvedic base. The therapeutic usage gives customer
loyalty leading to high gross margins, high barriers to entry, EDELWEISS CLASSIFICATION
strong brand equity, mass acceptance and superior growth
Market Cap Large Cap
opportunities.
Relative Risk High

 Emami has a superior track record of launching new brands Relative Reco Perform
(Fair & Handsome captures ~64% market share of men’s fairness Sector Rating Underweight
cream market) and transforming them into blockbusters.
Emami has also built other blockbuster brands such as Navratna
and Boroplus

 Introduction of lower SKUs for Zandu balm and rejuvenating

more than 200 of Zandu’s Ayurvedic-based prescription
products will be another growth driver for Emami. Emami is
slowly diversifying its portfolio (with foray into face wash, hair oils,
deodorants, female hygiene care) to insulate itself from
seasonal impact. Though we are enthused by Emami’s new
launch aggression it needs to sustain investment on innovation
and ad spends to remain competitive in the newer segments
(MNC competition high).

Risks
 Seasonality risk is one of the biggest risks to Emami. Summer
products’ (like Talc and cooling oil) and winter products’ (like
Boroplus) sales depend upon the weather conditions.
 Ayurvedic products are produced by more than a thousand
small companies in India, though only about a dozen are big
national players. Given Emami’s success, entry of new
competitors cannot be ruled out.

1 GWM
Edelweiss Ratios
Company Emami Dabur Marico
1 Wk Price performance (%) 6.2 0.7 3.1
3 M Price performance (%) 4.0 19.1 13.1
PE (x) 81.3 49.8 54.1
EV to EBITDA (x) 32.1 38.2 36.4
Return on Capital Employed (%) 23.5 30.5 47.1

Financial Snapshot
Year to March FY16 FY17 FY18E FY19E

Net Revenue 2,397 2,532 2,540 3,005

Revenue Growth (%) 18.3 5.7 1.5 18.7

EBITDA 687 759 719 871

Adjusted PAT 362 339 306 437

Adjusted diluted EPS (INR) 15.9 14.9 13.4 19.2
EPS Growth (%) -26 -6 -10 42.7
ROAE (%) 25.4 20.1 16.1 20.5

Technical View
S1 S2 R1 R2
Emami 1077 1035 1143 1175

2 GWM
 Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W)
Board: (91-22) 4272 2200

Vinay Khattar

Head Research

[email protected]

3 GWM
Disclaimer
Edelweiss Broking Limited (“EBL” or “Research Entity”) is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, depository
services and related activities. The business of EBL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing
and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID:
[email protected] Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts)
Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information
contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken
as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary
to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own
advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly
in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a
citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would
subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by
law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no
assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and
alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise
to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL
nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss
of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are
inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this
report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains,
unless otherwise stated, the copyright of EBL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of EBL and may not be
used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break
down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall
EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented
by the EBL through this report.
We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the
same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the
securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market
maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material
conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may
have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider
risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation
or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of
securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from
the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or
brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party
in connection with the research report. Research analyst or his/her relative or EBL’s associates may have financial interest in the subject company. EBL, its associates, research analyst and
his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research
report or at the time of public appearance.
Participants in foreign exchange transactions may incur risks arising from several factors, including the following: ( i) exchange rates can be volatile and are subject to large fluctuations; (
ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and
changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities
such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

EBL has financial interest in the subject companies: No

EBL’s Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of
research report.
Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication
of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No
Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.
A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:
The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities,
and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the“1934 act”) and under applicable state laws in the United States. In addition
Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

4 GWM
Disclaimer
applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the
products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an
advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US
Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").
In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within
Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Order”); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and
unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”).

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only
to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This
research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under
such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian
persons.
This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)
Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services
and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets,
Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary
action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation
22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.

5 GWM